@article{be11463bb68a4b6c914272dbfb8a83b8,
title = "Development of a self-efficacy questionnaire, {\textquoteleft}Insulin Therapy Self-efficacy Scale (ITSS){\textquoteright}, for insulin users in Japanese: The Self-Efficacy-Q study",
abstract = "Aims/Introduction: Although patient self-efficacy is known to affect adherence to therapy, no available tool measures self-efficacy of insulin therapy administration while addressing the entire therapeutic process and management. In light of this, we developed the {\textquoteleft}Insulin Therapy Self-efficacy Scale (ITSS).{\textquoteright}. Materials and Methods: Development of the ITSS involved three phases: (i) item generation and creation of a questionnaire draft; (ii) testing and correcting the items through interviews with patients; and (iii) a multicenter, single-arm study to validate the questionnaire. Results: A factor analysis and Cronbach's α both confirmed good internal consistency in the patients{\textquoteright} confidence regarding the following four factors: the insulin injection procedure, insulin titration, glycemic control and ability to cope with hypoglycemia. Reproducibility was confirmed using weighted κ statistics and intraclass correlations. Good concurrent validity was confirmed with two other questionnaires. The ITSS score was also found to correlate with several patient characteristics and clinical parameters, as well as with a better adherence to injected insulin therapy 6 months later, suggesting the predictive validity of this scale. Conclusions: The ITSS is a reliable and valid tool for assessing and quantifying patients{\textquoteright} self-efficacy. The ITSS estimation of self-efficacy can predict a patient's glycemic control and future adherence to insulin therapy. These characteristics will ensure the usefulness of the ITSS in ensuring a successful therapeutic process for patients and physicians.",
keywords = "Insulin Therapy Self-efficacy Scale (ITSS), Insulin therapy, Self-efficacy",
author = "Junko Nakaue and Miyuki Koizumi and Hiroki Nakajima and Sadanori Okada and Takako Mohri and Yasuhiro Akai and Miyuki Furuya and Yasuaki Hayashino and Yasunori Sato and Hitoshi Ishii",
note = "Funding Information: This investigator-sponsored trial was supported by Sanofi K.K. The authors thank Hirokazu Yamada of Soiken Inc. for providing editorial assistance, and Editage (www.editage.jp) for English language editing. Funding Information: JN received lecture and/or consultant fees from Sanofi K.K. HN received lecture and/or consultant fees from Astellas Pharma and Takeda Pharmaceutical Co. SO received lecture and/or consultant fees from MSD, Eli Lilly Japan, Takeda Pharmaceutical Co., Ono Pharmaceutical Co., Novo Nordisk Pharma Ltd., AstraZeneca K.K., Mitsubishi Tanabe Pharma, Boehringer Ingelheim Japan, Sanofi and Arkray. TM received lecture and/or consultant fees from Novo Nordisk Pharma Ltd., Takeda Pharmaceutical Co., Boehringer Ingelheim Japan and Eli Lilly Japan. YA received lecture fees from MSD K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K., Torii Pharmaceutical Co., Ltd., Teijin Pharma Limited, Sanofi K.K., Kowa Pharmaceutical Company Ltd., Chugai Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., Baxter Limited, Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Boehringer Ingelheim Japan, Inc., Astellas Pharma Inc. and Kyowa Hakko Kirin Co., Ltd. YH received personal fees from Takeda Pharmaceutical Company, Ltd., Eli Lilly Japan K.K., Daiichi Sankyo Company, Ltd., Teijin Pharma, Ltd., Ono Pharmaceutical Co., Ltd, Novo Nordisk Pharma Ltd., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corporation, AstraZeneca Pharma, Ltd, Merck & Co., Inc., Kyowa Hakko Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd. and Berlinger & Co., AG., outside the submitted work. HI has received research grants from AstraZeneca K.K.; honoraria from Ono Pharmaceutical Co., Shionogi, Mit-subishi Tanabe Pharma, Arkray, MSD, Taisho Toyama Pharmaceutical Co., Becton Dickinson Japan, Novo Nordisk Pharma Ltd., Daiichi Sankyo, Takeda Pharmaceutical Co., Astellas Pharma and Boehringer Ingelheim Japan; and lecture and/or consultant fees from Takeda Pharmaceutical Co. Eli Lilly Japan, Sanofi, MSD, Astellas Pharma, Novartis Pharma, Mitsubishi Tanabe Pharma, Daiichi Sankyo, Ono Pharmaceutical Co., AstraZeneca K.K., Taisho Toyama Pharmaceutical, Shionogi, Kowa Pharmaceutical Co., Boehringer Ingelheim Japan, Novo Nordisk Pharma Ltd., Sumitomo Dainippon Pharma, Kyowa Hakko Kirin, Terumo Co., Bristol-Myers Squibb Co., Sanwa Kagaku Kenkyusho Co. Ltd., Fujirebio Inc., Kowa Pharmaceutical, Pfizer and Teijin Pharma. All other authors declare no conflict of interest. Publisher Copyright: {\textcopyright} 2018 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd",
year = "2019",
month = mar,
doi = "10.1111/jdi.12914",
language = "English",
volume = "10",
pages = "358--366",
journal = "Journal of Diabetes Investigation",
issn = "2040-1116",
publisher = "Blackwell Publishing Asia Pty Ltd",
number = "2",
}